Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.
Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterized by microangiopathy with progressive loss of capillaries and tissue fibrosis. Imatinib exerts potent anti-fibrotic effects and is currently evaluated in clinical trials. The aim of the present study was to exclude that the anti-fibrotic effects of imatinib are complicated by inhibitory effects on endothelial cell functions, which might augment vascular disease in SSc. Endothelial cells and mice were treated with pharmacologically relevant concentrations of imatinib. The expression of markers of vascular activation was assessed with real-time PCR. Proliferation was analysed with the cell counting experiments and the MTT assay. Apoptosis was quantified with caspase 3 assays, annexin V in vitro and with TUNEL staining in vivo. Migration was studied with scratch and transwell assays. Tube forming was investigated with the matrigel assay. Imatinib did not alter the expression of markers of vascular activation. Imatinib did not increase the percentage of annexin V positive cells or the activity of caspase 3. No reduction in proliferation or metabolic activity of endothelial cells was observed. Imatinib did not affect migration of endothelial cells and did not reduce the formation of capillary tubes. Consistent with the in vitro data, no difference in the number of apoptotic endothelial cells was observed in vivo in mice treated with imatinib. Imatinib does not inhibit activation, viability, proliferation, migration or tube forming of endothelial cells in vitro and in vivo. Thus, treatment with imatinib might not augment further endothelial cell damage in SSc.
Venalis
Paulius
P
Department for Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Maurer
Britta
B
Akhmetshina
Alfiya
A
Busch
Nicole
N
Dees
Clara
C
Stürzl
Michael
M
Zwerina
Jochen
J
Jüngel
Astrid
A
Gay
Steffen
S
Schett
Georg
G
Distler
Oliver
O
Distler
Jörg H W
JH
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D015415:Biomarkers / Q000378:metabolism; D001808:Blood Vessels / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002633:Chemotaxis / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D005355:Fibrosis; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D009389:Neovascularization, Pathologic / Q000473:pathology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D015203:Reproducibility of Results
D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
Angiogenesis. 2007;10(4):279-86
17876712
J Pathol. 2006 Oct;210(2):240-8
16917801
Arthritis Rheum. 2008 May;58(5):1475-84
18438865
Am J Pathol. 2006 Dec;169(6):2254-65
17148686
Rheumatology (Oxford). 2008 May;47(5):735-7
18326532
Expert Opin Ther Targets. 2007 Sep;11(9):1207-17
17845146
N Engl J Med. 2002 Feb 28;346(9):683-93
11870247
Arthritis Rheum. 2008 Aug;58(8):2543-8
18668587
Am J Respir Crit Care Med. 2008 Jul 1;178(1):81-8
18420966
Arthritis Rheum. 2007 Jan;56(1):311-22
17195235
J Invest Dermatol. 1992 Dec;99(6):683-90
1361507
J Clin Invest. 2007 Mar;117(3):557-67
17332883
Arthritis Rheum. 2008 Aug;58(8):2538-42
18668536
Nat Med. 2006 Aug;12(8):908-16
16862153
J Chemother. 2006 Feb;18(1):56-65
16572895
Ann Rheum Dis. 2007 Jun;66(6):836
17513571
J Clin Invest. 2004 Nov;114(9):1308-16
15520863
Apoptosis. 2005 Aug;10(4):731-41
16133865